B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial

Abstract

Aim: We here assessed the impact of B-cell receptor stereotypy on progression-free survival (PFS) and overall survival in patients from the HOVON 68 trial.

Methods: Based on IGHV mutational analyses from participating centers in Sweden, Norway, Finland, Denmark, Poland, and the Netherlands, B-cell receptor stereotyped subsets were assigned using the ARResT/AssignSubsets software. Analysis for recurrent mutations was performed by next-generation sequencing by a 454-base platform. All other clinical data were extracted from the HOVON database by November 2016.

Results: In total, 178 out of 192 patients with sequences available were technically suitable for analysis. Thirty-eight patients (21%) were assigned to one of the 19 major subsets: Subset #2 (n = 12, 6.7%), Subset #8 (n = 7, 3.9%), Subset #6 (n = 6, 3.4%), and Subset #1 (n = 5, 2.8%). Other subsets found were: Subsets #3, #5, #31, and #64B. By November 2016, a PFS event had occurred for 150 patients (84%) and 79 patients (44%) had died. The median follow-up time for patients still alive was 78.9 months. Patients with UM-IGHV belonging to Subset #2 had significantly longer PFS than UM-IGHV 3-21-utilizing non-Subset #2 patients [UM-IGHV Subset #2 median PFS 61.3 months (n = 8) vs. UM-IGHV 3-21 non-Subset #2 median PFS 22.3 months (n = 6), P = 0.01]. Overall, no significant differences in PFS between groups were found for patients with M-IGHV.

Conclusion: In the HOVON 68 trial. Subset #2 patients had a good treatment outcome comparable to the outcome for non-high-risk patients with chronic lymphocytic leukemia following fludarabine-cyclophosphamide-rituximab-based treatment.

Keywords

Chronic lymphocytic leukemia / B-cell stereotypy subsets / treatment outcome

References

[1] JaramilloS,SchneiderC.Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).Haematologica2020;105:2598-607 PMCID:PMC7604575

[2] GeislerCH,JurlanderJ.Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.Blood2014;123:3255-62

[3] AgathangelidisA,HadzidimitriouA.Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.Blood2012;119:4467-75 PMCID:PMC3392073

[4] AgathangelidisA,GemenetziK.Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.Blood2021;137:1365-76 PMCID:PMC7976441

[5] BaliakasP,SuttonL.Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.Lancet Haematol2014;1:e74-84

[6] TobinG,JohnsonA.Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.Blood2003;101:4952-7

[7] BystryV,BikosV.European Research Initiative on CLLARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy.Bioinformatics2015;31:3844-6

[8] JethwaA,StolzT.Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.Br J Haematol2013;163:496-500

[9] EichhorstB,BahloJ.First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.Lancet Oncol2016;17:928-42

[10] JerominS,DickerF,HaferlachT.Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations.Leukemia2016;30:2251-3

[11] JerominS,HaferlachC.SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.Leukemia2014;28:108-17

[12] BaliakasP,HadzidimitriouA.Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.Blood2015;125:856-9 PMCID:PMC4311230

[13] BhoiS,BaliakasP.Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2.Epigenetics2016;11:449-55 PMCID:PMC4939912

[14] BaliakasP,HadzidimitriouA.No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.Haematologica2018;103:e158-61 PMCID:PMC5865420